从社会视角出发继续前行：关于生产力成本、消费成本和非正式护理成本的专题文章 - Suppr

Suppr

超能文献

Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs.

作者信息

Brouwer Werner, van Baal Pieter

机构信息

Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

出版信息

Pharmacoeconomics. 2023 Sep;41(9):1027-1030. doi: 10.1007/s40273-023-01307-1. Epub 2023 Aug 2.

DOI:10.1007/s40273-023-01307-1

PMID:37530935

Abstract

摘要

相似文献

Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs.从社会视角出发继续前行：关于生产力成本、消费成本和非正式护理成本的专题文章

Pharmacoeconomics. 2023 Sep;41(9):1027-1030. doi: 10.1007/s40273-023-01307-1. Epub 2023 Aug 2.

The economic burden of prostate cancer - a Swedish prevalence-based register study.前列腺癌的经济负担——一项基于瑞典患病率的登记研究。

BMC Health Serv Res. 2020 May 20;20(1):448. doi: 10.1186/s12913-020-05265-8.

Patients' productivity losses and informal care costs related to ischemic stroke: a French population-based study.与缺血性脑卒中相关的患者生产力损失和非正式护理成本：一项基于法国人群的研究。

Eur J Neurol. 2021 Feb;28(2):548-557. doi: 10.1111/ene.14585. Epub 2020 Nov 6.

Economic Analysis of Formal Care, Informal Care, and Productivity Losses in Primary Care Patients who Screened Positive for Dementia in Germany.德国痴呆症筛查呈阳性的初级护理患者的正规护理、非正规护理及生产力损失的经济分析

J Alzheimers Dis. 2016;50(1):47-59. doi: 10.3233/JAD-150600.

The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care.2012年瑞典痴呆症的社会成本——评估非正式护理的相关性及方法挑战

Alzheimers Res Ther. 2016 Nov 18;8(1):59. doi: 10.1186/s13195-016-0215-9.

Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method.基于机会成本和代理商品法的非正规护理成本测量、评估和估算的标准化问卷。

Appl Health Econ Health Policy. 2019 Feb;17(1):15-24. doi: 10.1007/s40258-018-0418-2.

Intervention and societal costs of residential community reintegration for patients with acquired brain injury: a cost-analysis of the Brain Integration Programme.康复社区介入对脑外伤患者的社会成本：脑整合计划的成本分析。

J Rehabil Med. 2011 Jun;43(7):647-52. doi: 10.2340/16501977-0818.

Disease burden of patients with pemphigus from a societal perspective.从社会角度看天疱疮患者的疾病负担。

Expert Rev Pharmacoecon Outcomes Res. 2021 Feb;21(1):77-86. doi: 10.1080/14737167.2020.1722104. Epub 2020 Jan 28.

The societal costs of chronic pain and its determinants: The case of Austria.慢性疼痛及其决定因素的社会成本：以奥地利为例。

PLoS One. 2019 Mar 20;14(3):e0213889. doi: 10.1371/journal.pone.0213889. eCollection 2019.

Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial.痴呆症初级保健患者的医疗利用和费用：DelpHi 试验的基线结果。

Eur J Health Econ. 2018 Jan;19(1):87-102. doi: 10.1007/s10198-017-0869-7. Epub 2017 Feb 3.

引用本文的文献

Combating Antimicrobial Resistance Through a Data-Driven Approach to Optimize Antibiotic Use and Improve Patient Outcomes: Protocol for a Mixed Methods Study.通过数据驱动的方法来优化抗生素使用并改善患者结局以对抗抗菌药物耐药性：一项混合方法研究的方案。

JMIR Res Protoc. 2024 Nov 8;13:e58116. doi: 10.2196/58116.

A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries.低、中收入国家因病缺勤和照顾病患导致生产力损失的估算方法系统评价

Pharmacoeconomics. 2024 Aug;42(8):865-877. doi: 10.1007/s40273-024-01402-x. Epub 2024 Jun 14.

本文引用的文献

Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada.基于药物基因组学（PGx）的华法林、阿哌沙班和利伐沙班与标准华法林治疗加拿大安大略省心房颤动的成本效益分析。

Pharmacoeconomics. 2024 Jan;42(1):69-90. doi: 10.1007/s40273-023-01309-z. Epub 2023 Aug 19.

Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review.纳入健康经济评估的乘数效应和补偿机制：系统评价。

Pharmacoeconomics. 2023 Sep;41(9):1031-1050. doi: 10.1007/s40273-023-01304-4. Epub 2023 Aug 17.

Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework.估算加速审批药物确证性试验的潜在获益：综合信息价值框架。

Pharmacoeconomics. 2023 Dec;41(12):1617-1627. doi: 10.1007/s40273-023-01303-5. Epub 2023 Jul 25.

Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort.家庭中为残疾或老年成员提供非正式护理与工作生产力：来自澳大利亚基于人群的 11 波队列研究的证据。

Pharmacoeconomics. 2023 Sep;41(9):1117-1136. doi: 10.1007/s40273-023-01283-6. Epub 2023 Jun 20.

Cost-Effectiveness Analysis of MammaPrint to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer.MammaPrint 用于指导早期乳腺癌患者内分泌治疗的成本效益分析。

Pharmacoeconomics. 2023 Aug;41(8):981-997. doi: 10.1007/s40273-023-01277-4. Epub 2023 May 28.

Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics.使用 EQ-5D-5L 衡量疾病的间接成本，并考虑工作特征。

Pharmacoeconomics. 2023 Sep;41(9):1051-1064. doi: 10.1007/s40273-023-01267-6. Epub 2023 May 6.

Productivity Loss Across Socioeconomic Groups Among Patients With Low Back Pain or Osteoarthritis: Estimates Using the Friction-Cost Approach in Norway.社会经济群体中腰痛或骨关节炎患者的生产力损失：挪威采用摩擦成本法的估计。

Pharmacoeconomics. 2023 Sep;41(9):1079-1091. doi: 10.1007/s40273-023-01269-4. Epub 2023 Apr 21.

The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.健康的价值在成本效益分析中的体现：理论与实践。

Pharmacoeconomics. 2023 Jun;41(6):607-617. doi: 10.1007/s40273-023-01265-8. Epub 2023 Apr 18.

Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries.估算经济评估的全球摩擦期：以部分经合组织成员国为例。

Pharmacoeconomics. 2023 Sep;41(9):1093-1101. doi: 10.1007/s40273-023-01261-y. Epub 2023 Apr 10.

Distributional consequences of including survivor costs in economic evaluations.将生存者成本纳入经济评估的分配后果。

Health Econ. 2021 Sep;30(10):2606-2613. doi: 10.1002/hec.4401. Epub 2021 Jul 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验